Competition closes: 6th September 2021, 1pm
Applicants notified: 18th October 2021
Stage 2 deadline (if invited): 22nd November 2021 – with outcome Feb 2022
Project duration: Typically 12-36 months.
Your project must align with one of the following phases (2-4)
- Phase 2 is intended to develop and evaluate prototypes of demonstration units and generate early clinical safety and efficacy data.
- Phase 3 is intended to support first real-world testing in health and social care settings to develop further evidence of efficacy and preliminary proof of effectiveness, including evidence for routes to implementation to enable more rapid adoption.
- Phase 4 is intended to identify medium stage AI technologies that have market authorisation but insufficient evidence to merit large-scale commissioning or deployment. We will support testing and evaluation of these technologies within routine clinical or operational pathways to determine efficacy or accuracy, and clinical and economic impact.
- Health promotion and prevention
- Digital epidemiology and disease surveillance
- National screening programmes
- Preventative advice
- Diagnosis and treatment
- Symptoms checkers and decision support for differential diagnosis
- Risk stratification
- Prediction of deterioration
- Personalised treatments
- System efficiency
- Optimisation of care pathways
- Identification of resource requirements
- Electronic roster system
- Natural Language Processing for administrative tasks
- Applications may be submitted by a small-to-medium-sized enterprise (SME), an NHS or social care organisation or service provider, a higher education institution, charity or local authority. Additionally, for Phases 3 and 4, the call is open to large enterprises.
- Payments will be made to the contracted organisation only and the contracted organisation will be responsible for passing on any money due to their partner organisation
- 100% of direct costs will be funded
- Award amounts are uncapped (any amount can be requested but must be reasonably justified).